Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2013 (2013), Article ID 728371, 2 pages
http://dx.doi.org/10.1155/2013/728371
Case Report

Case Report of Transverse Myelitis in a Patient Receiving Etanercept for Rheumatoid Arthritis

Rheumatology Department, St. Peters Hospital, Guilford Road, Chertsey, Surrey KT16 0PZ, UK

Received 5 January 2013; Accepted 12 February 2013

Academic Editors: G. S. Alarcon, S. S. Koca, and A. Zoli

Copyright © 2013 Helen Defty et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Singh, R. Christensen, G. A. Wells et al., “Biologics for rheumatoid arthritis: an overview of Cochrane reviews.,” Cochrane database of systematic reviews (Online), vol. 7, no. 4, p. CD007848, 2009. View at Google Scholar · View at Scopus
  2. National Institute of Clinical Excelence (NICE), “Guidance on the use of Etanercept and infliximab for the treatment of rheumatoid arthritis,” Technology Appraisal Guidance 36, National Institute of Clinical Excelence (NICE), London, UK, 2002. View at Google Scholar
  3. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, “TNF neutralization in MS: results of a randomized, placebo-controlled multicentre study,” Neurology, vol. 53, no. 3, pp. 457–465, 1999. View at Publisher · View at Google Scholar
  4. C. W. Lees, A. I. Ali, A. I. Thompson et al., “The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up,” Alimentary Pharmacology and Therapeutics, vol. 29, no. 3, pp. 286–297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Bernatsky, C. Renoux, and S. Suissa, “Demyelinating events in rheumatoid arthritis after drug exposures,” Annals of the Rheumatic Diseases, vol. 69, no. 9, pp. 1691–1693, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Alshekhlee, K. Basiri, J. D. Miles, S. A. Ahmad, and B. Katirji, “Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists,” Muscle and Nerve, vol. 41, no. 5, pp. 723–727, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Tristano, “Neurological adverse events associated with anti-tumor necrosis factor alpha treatment,” Journal of Neurology, vol. 257, no. 9, pp. 1421–1431, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. P. Stubgen, “Tumor necrosis factor-alpha antagonists and neuropathy,” Muscle and Nerve, vol. 37, no. 3, pp. 281–292, 2008. View at Publisher · View at Google Scholar